Decisions analysed
Find a decision of the Unified Patent Court, consult its official source and identify the firm’s case notes to understand its practical implications.
Find a decision in three steps
- 1. SearchEnter a party name, case number or keyword.
- 2. RefineUse the filters to refine your search, then select Filter.
- 3. ReadOpen a title. The “Decision with commentary” badge identifies a case note by the firm.
Scope, method and reading key
UPC decisions and orders since 1 June 2023. “Decision with commentary” means the entry contains an analysis by Dhenne Avocats. “Summary available” identifies a summary; “Reference” identifies a record without a detailed case note. Open the entry for the source and, where available, the facts, reasoning and practical implications. The official decision is authoritative.
Advanced search
Combinable filters, search within the records or the full text of the decisions, copy reference, selection and export. The keyword and reference search above remains available.
Compare two parties or two issues
127 decisions match these criteria.
Zentiva France v Sanofi Mature IP (CFI, 24 January 2025)
In a procedural order of 24 January 2025, the Munich Local Division set the timetable for the proceedings on EP 2 493 466 between the Sanofi companies and Accord Healthcare, STADA, Dr Reddy’s and Zentiva (UPC_CFI_145, 146, 147, 148, 374, 463, 496…
Read the analysisSanofi Winthrop Industrie v Accord Healthcare (CFI, 22 January 2025)
By a common order of 22 January 2025, issued after the preliminary interim conference in Sanofi's four joined infringement actions against Accord, Stada, Reddy and Zentiva (UPC_CFI_145/2024 to UPC_CFI_148/2024, EP 2 493 466, cabazitaxel), the judge-rapporteur of the Munich Local Division (Judge…
Read the analysisSanofi Mature IP v Accord Healthcare (CFI, 17 January 2025)
By order of 17 January 2025, Presiding Judge Matthias Zigann, acting as judge-rapporteur of panel 1 of the Munich Local Division, substituted Sanofi SA for Sanofi Mature IP, claimant no.
Read the analysisEOFLOW v Insulet (CoA, 10 January 2025)
By order of 9 January 2025 (UPC_CoA_584/2024), the Court of Appeal disposed of EOFlow’s appeal as devoid of purpose. The appeal challenged the Milan Central Division’s order of 24 September 2024 refusing to join Insulet’s application for provisional measures against EOFlow (EP…
Read the analysisInsulet v A. Menarini Diagnostics (CoA, APL_64383/2024, 9 January 2025)
By order of 9 January 2025 (UPC_CoA_769/2024), the judge-rapporteur of the Court of Appeal held that A. Menarini Diagnostics’ confidentiality request in Insulet’s appeal against the Milan Local Division’s refusal of provisional measures (EP 4 201 327) was superfluous.
Read the analysisSanofi Mature IP v Accord Healthcare (CFI, 7 January 2025)
By an order of 7 January 2025, made in the parallel infringement actions on EP 2 493 466 (UPC_CFI_145/2024 to UPC_CFI_148/2024, against Accord Healthcare, STADA, Reddy and Zentiva), Judge Zigann, judge-rapporteur at the Munich Local Division, substituted Sanofi Winthrop Industrie for Sanofi-Aventis…
Read the analysisInsulet v Eoflow (CFI, 30 December 2024)
By an order of 30 December 2024 (UPC_CFI_400/2024, ORD_60558/2024), the judge-rapporteur of the Milan Local Division (Judge Zana) dismissed Insulet's application for a costs decision against Eoflow, whose application to intervene in support of A.
Read the analysisAdvanced Bionics v MED-EL Elektromedizinische Geräte (CFI, 26 December 2024)
Read the French analysisInsulet v A. Menarini Diagnostics (CFI, 23 December 2024)
By an order of 23 December 2024 (UPC_CFI_380/2024, ORD_59988/2024), the judge-rapporteur of the Milan Central Division (Judge Postiglione) ordered A. Menarini Diagnostics to pay Insulet EUR 1,764 for the costs of opposing its application to intervene, refused on 1 October 2024, in…
Read the analysisAlexion Pharmaceuticals v Samsung Bioepis NL (CoA, 20 December 2024)
In an order of 20 December 2024 (UPC_CoA_402/2024), the Court of Appeal dismissed Alexion’s appeal against the Hamburg Local Division’s refusal to grant provisional measures against Samsung Bioepis’s marketing of Epysqli®, a biosimilar of Soliris® (eculizumab), under EP 3 167 888.
Read the analysisG. Pohl-Boskamp v pharma-aktiva (CFI, 20 December 2024)
By an order of 20 December 2024 (UPC_CFI_541/2024), made after an oral hearing, the Mannheim Local Division (Judge Tochtermann presiding, Judge Böttcher as judge-rapporteur, Judge Mlakar) granted G.
Read the analysisAlexion Pharmaceuticals v Amgen Technology (Ireland) Unlimited Company (CoA, 20 December 2024)
In an order of 20 December 2024 (UPC_CoA_405/2024), the Court of Appeal dismissed Alexion’s appeal against the Hamburg Local Division’s refusal to grant provisional measures against Amgen’s marketing of BEKEMV®, a biosimilar of Soliris® (eculizumab), under EP 3 167 888.
Read the analysisInsulet v A. Menarini Diagnostics (CFI, 22 November 2024)
By order of 22 November 2024 (UPC_CFI_400/2024, App_40442/2024), made after the hearing of 15 October 2024, the Milan Local Division (panel presided over by P. Perrotti) dismissed Insulet Corporation's application for provisional measures against A.
Read the analysisInsulet v EOFLOW (CFI, 22 November 2024)
By order of 22 November 2024 (UPC_CFI_380/2024), made after the hearing of 16 October 2024, the Milan Central Division (panel presided over by A. Postiglione) dismissed Insulet Corporation's application for provisional measures against EOFLOW Co., Ltd.
Read the analysisEOFLOW v Insulet (CoA, 9 October 2024)
In an order of 9 October 2024 (UPC_CoA_584/2024), the Court of Appeal refused EOFlow’s request to expedite its appeal against the order of 24 September 2024 of the Milan Central Division, which had declined to join Insulet’s application for provisional measures against…
Read the analysisA. Menarini Diagnostics v Insulet (CFI, 1 October 2024)
By order of 1 October 2024 (UPC_CFI_400/2024, ORD_51903/2024, App_40442/2024), the Milan Local Division (P. Perrotti, presiding, A.
Read the analysisEOFLOW v Insulet (CFI, 1 October 2024)
By order of 1 October 2024 (UPC_CFI_380/2024, ORD_52068/2024), the Milan Central Division (A. Postiglione, presiding and judge-rapporteur, A.-L.
Read the analysisInsulet v A. Menarini Diagnostics (CFI, 1 October 2024)
By order of 1 October 2024 (UPC_CFI_400/2024), the Milan Local Division dismissed the application of EOFlow, the manufacturer of the EOPatch insulin patch pump, to intervene in support of its exclusive distributor A.
Read the analysisEOFLOW v INSULET (CFI, 24 September 2024)
By an order of 24 September 2024 (UPC_CFI_380/2024), the panel of the Milan Central Division (A. Postiglione, presiding judge and judge-rapporteur, A.-L.
Read the analysisNovartis v Celltrion Healthcare Hungary (CFI, 6 September 2024)
By order of 6 September 2024 (UPC_CFI_165/2024, ACT_18492/2024), the Düsseldorf Local Division (R. Thomas, presiding, B.
Read the analysisNovartis v Celltrion (CFI, 6 September 2024)
By order of 6 September 2024 (UPC_CFI_166/2024, ACT_18551/2024), the Düsseldorf Local Division (R. Thomas, presiding, B.
Read the analysisAdvanced Bionics v MED-EL Elektromedizinische Geräte Gesellschaft m.b.H. (CoA, ORD_42780/2024, 5 September 2024)
By order of 5 September 2024 (UPC_CoA_106/2024, APL_12739/2024), the Court of Appeal (K. Grabinski, presiding, P.
Read the analysisAdvanced Bionics v MED-EL Elektromedizinische Geräte Gesellschaft m.b.H. (CoA, ORD_42779/2024, 5 September 2024)
By order of 5 September 2024 (UPC_CoA_207/2024, APL_24598/2024), the Court of Appeal dismissed Advanced Bionics' appeal against the order of the President of the Court of First Instance of 15 April 2024, which had refused to replace German with English, the language…
Read the analysisA. Menarini Diagnostics v Insulet (CFI, 4 September 2024)
By order of 4 September 2024 (UPC_CFI_400/2024, ORD_45723/2024, App_45575/2024), the Milan Local Division (P. Perrotti, presiding, A.
Read the analysisAlexion Pharmaceuticals v Amgen Technology (Ireland) (CoA, 8 August 2024)
Read the French analysisAlexion Pharmaceuticals v Samsung Bioepis NL (CoA, 30 July 2024)
By order of 30 July 2024 (UPC_CoA_402/2024, APL_40470/2024), the Court of Appeal rejected Alexion Pharmaceuticals' request to expedite its appeal against the Hamburg Local Division's dismissal of its application for provisional measures against Samsung Bioepis NL on EP 3 167 888.
Read the analysis